Primary versus interval cytoreductive surgery in patients with rare epithelial or non-epithelial ovarian cancer
- 28 January 2025
- journal article
- review article
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 35 (3) , 101664
Abstract
No abstract availableKeywords
This publication has 55 references indexed in Scilit:
- ESGO–ESMO–ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent diseaseAnnals of Oncology, 2024
- Uptake and Outcomes of Neoadjuvant Chemotherapy Among US Patients With Less Common Epithelial Ovarian CarcinomasJAMA Network Open, 2023
- Chemotherapy response in low‐grade serous ovarian carcinoma at a comprehensive cancer center: Readdressing the roles of platinum and cytotoxic therapiesCancer, 2023
- Low-Grade Serous Ovarian Carcinoma: a Retrospective Study from a Tertiary Cancer InstituteIndian Journal of Surgical Oncology, 2022
- Impact of cytoreductive surgery on survival of patients with low‐grade serous ovarian carcinoma: A multicentric study of Turkish Society of Gynecologic Oncology (TRSGO‐OvCa‐001)Journal of Surgical Oncology, 2021
- Comparison of survival between primary debulking surgery and neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers in phase III randomised trialEuropean Journal of Cancer, 2020
- Chemotherapy alone for patients 75 years and older with epithelial ovarian cancer—is interval cytoreductive surgery still needed?American Journal of Obstetrics and Gynecology, 2020
- Retrospective Analysis of 32 Cases of Ovarian Granulosa Cell TumoursThe Journal of Obstetrics and Gynecology of India, 2019
- Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trialsCancer, 2009
- Advanced stage mucinous epithelial ovarian cancer: The Hellenic Cooperative Oncology Group experienceGynecologic Oncology, 2005